Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Operating Leases (2021 - 2025)

Prime Medicine filings provide 5 years of Operating Leases readings, the most recent being $108.3 million for Q4 2025.

  • On a quarterly basis, Operating Leases rose 191.26% to $108.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $108.3 million, a 191.26% increase, with the full-year FY2025 number at $108.3 million, up 191.26% from a year prior.
  • Operating Leases hit $108.3 million in Q4 2025 for Prime Medicine, down from $118.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $118.1 million in Q3 2025 to a low of $3.1 million in Q4 2021.
  • Median Operating Leases over the past 5 years was $19.9 million (2022), compared with a mean of $37.8 million.
  • Biggest five-year swings in Operating Leases: skyrocketed 753.34% in 2024 and later crashed 83.63% in 2025.
  • Prime Medicine's Operating Leases stood at $3.1 million in 2021, then skyrocketed by 455.41% to $17.1 million in 2022, then crashed by 74.45% to $4.4 million in 2023, then skyrocketed by 753.34% to $37.2 million in 2024, then skyrocketed by 191.26% to $108.3 million in 2025.
  • The last three reported values for Operating Leases were $108.3 million (Q4 2025), $118.1 million (Q3 2025), and $112.5 million (Q2 2025) per Business Quant data.